BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...work with discovery partnerships, but none has yet produced a clinical candidate. In addition, senrebotase (AGN-214868...
...up to €130 million ($169.8 million) in milestones. The deal included senrebotase ( AGN-214868 ; SXN100323...
BioCentury | Jul 22, 2013
Finance

Highlights of weekly biotech stock moves

...million) in milestones. Ipsen gains Syntaxin's patent portfolio related to botulinum toxin biology. AGN-214868 ( SXN100323...
BioCentury | Jul 22, 2013
Company News

Ipsen, Syntaxin, Harvard deal

...2011 to discover and develop compounds to treat botulinum toxin. Syntaxin's senrebotase ( AGN-214868 , SXN100323...
BioCentury | Jul 16, 2013
Company News

Ipsen acquires Syntaxin

...Syntaxin partnered in 2011 to discover and develop compounds to treat botulinum toxin. Syntaxin's AGN-214868 (SXN100323...
BioCentury | Mar 14, 2011
Clinical News

AGN-214868: Phase II started

...began a double-blind, placebo-controlled, international Phase II trial to evaluate 500, 1,000 and 2,000 ng AGN-214868...
...BioCentury, Sept. 11, 2006). Syntaxin Ltd. , Abingdon, U.K. Allergan Inc. (NYSE:AGN), Irvine, Calif. Product: AGN-214868...
BioCentury | Mar 14, 2011
Clinical News

AGN-214868: Phase II started

...Allergan began a double-blind, placebo-controlled, international Phase II trial to evaluate 3,250 and 16,250 ng AGN-214868...
...BioCentury, Sept. 11, 2006). Syntaxin Ltd. , Abingdon, U.K. Allergan Inc. (NYSE:AGN), Irvine, Calif. Product: AGN-214868...
Items per page:
1 - 6 of 6